$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
News
News
Medical Halo Global Pharmaceutical News_Targeted Drugs_New Anti-Cancer Drugs_Overseas Medical Information_【Medical Halo Global Pharmaceutical】
How long does it take to take Cabergoline to achieve the desired effect?
2026-02-01 22:25:32
Check Details
Analysis of detailed Chinese instructions and medication guide for Momelotinib
2026-02-01 22:25:32
Check Details
The correct taking time and optimal daily dosing schedule of Bikken Pronol Tablets (Bituvi)
2026-02-01 22:25:32
Check Details
Will disease relapse years after stopping deuterated colexitinib?
2026-02-01 22:25:32
Check Details
Is Apremilast (Otelor) a hormonal drug and is it safe for long-term use?
2026-02-01 22:25:32
Check Details
Disease types and treatment suggestions for Valganciclovir
2026-02-01 22:25:32
Check Details
Full interpretation of the launch date, indications and domestic sales of voclosporin soft capsules
2026-02-01 22:25:32
Check Details
Whether ponatinib has been included in medical insurance and a comprehensive analysis of the latest reimbursement policy and self-payment situation
2026-02-01 22:25:32
Check Details
What kind of medicine is Shafinamide Tablets (Siddaco)? Analysis of indications, pharmacological effects and clinical uses
2026-02-01 22:25:32
Check Details
Tarlatamab-Imdelltra’s domestic launch time, approval status and sales channel description
2026-02-01 22:25:32
Check Details
Telisotuzumab-EMRELIS is developed and produced by which company and drug qualification description
2026-02-01 22:25:32
Check Details
Analysis of whether tovorafenib has been included in medical insurance and the reimbursement policy and cost description in 2025
2026-02-01 22:25:32
Check Details
1
2
...
2269
2270
2271
2272
2273
2274
2275
...
10228
10229
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Lapatinib Side Effects: Managing Diarrhea, Skin Reactions, and Liver Function Changes
2
Trelagliptin: A Once-Weekly Long-Acting Oral DPP-4 Inhibitor
3
Neurokinin Receptor Antagonists: A Non-Hormonal Approach to Menopausal Hot Flashes and Sleep Disturbances
4
Cemiplimab: A PD-1 Checkpoint Inhibitor for Skin Cancers and Non-Small Cell Lung Cancer
5
Nintedanib: A Multi-Target Antifibrotic Agent for Slowing Pulmonary Fibrosis Progression
6
Capmatinib (Tabrecta): Generational Positioning, Adverse Effect Incidence, and Comprehensive Management
7
Gilteritinib (XOSPATA): Dosing Cycle, Treatment Duration, and Development Background
8
Dabrafenib (TAFINLAR): Indications, Adverse Effect Management, and Dose Modification Guide
9
Adagrasib (Krazati): A Complete Guide to Side-Effect Recognition and Grade-Based Management
10
Tepotinib (TEPMETKO): Complete Dosing, Side-Effect Management, and Discontinuation Guide
11
Valganciclovir (Valcyte) in Post-Transplant CMV Management: A Comprehensive Guide
12
Tivozanib Dosage and Administration: Standard Dosing, Cycle Schedule, and Hepatic Impairment Adjustments